SCHEMBL12439392

SCHEMBL12439392

COC(=O)N1CCC(C(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.42
CHRNA4 P43681 2/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
HSD11B1 P28845 1/20 0.39
TSHR P16473 1/20 0.38
CYP2D6 P10635 2/20 0.38
PDE4B Q07343 3/20 0.37
PDE4A P27815 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
MMP7 P09237 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12384735 0.89 CYP1A2 (0.41) CHRNB2CHRNA4CHRNB4CHRNA3CYP1A2
SCHEMBL22971690 0.89 CYP1A2 (0.41) CHRNB2CHRNA4CHRNB4CHRNA3CYP1A2
SCHEMBL2603248 0.89 CYP1A2 (0.45) CHRNB2CHRNA4CHRNB4CHRNA3CYP1A2
SCHEMBL21025382 0.84 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3CYP1A2
SCHEMBL12142025 0.84 GAA (0.53) TSHRTHRBATML3MBTL1GAA
SCHEMBL12988840 0.82 CYP1A2 (0.44) CYP1A2CYP2C9CYP2D6MMP1MMP2
SCHEMBL23261698 0.81 CHRNB2 (0.40) CHRNB2CHRNA4CHRNB4CHRNA3CYP1A2
SCHEMBL21316612 0.81 HPGD (0.49) EPHX1L3MBTL1ALDH1A1
SCHEMBL4546635 0.81 HPGD (0.49) EPHX1L3MBTL1ALDH1A1
SCHEMBL14024977 0.81 HPGD (0.49) EPHX1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023172737-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-09-14 WO disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-8884030-B2 Inhibitors of Flaviviridae viruses GILEAD SCIENCES, INC. (US) 2014-11-11 US disclosed
US-8524764-B2 Inhibitors of Flaviviridae viruses GILEAD SCIENCES, INC. (US) 2013-09-03 US disclosed
US-20110178058-A1 INHIBITORS OF FLAVIVIRIDAE VIRUSES GILEAD SCIENCES, INC. (US) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178058-A1 INHIBITORS OF FLAVIVIRIDAE VIRUSES HAVCR2, CYP2F1, CYP4F3 CHRNB2 4880/4885CHRNA4 4852/4885CHRNB4 4871/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CHRNB2 3146/4885CHRNA4 3801/4885CHRNB4 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.